Inferring therapeutic targets from heterogeneous data: HKDC1 is a novel potential therapeutic target for cancer

Bioinformatics

Volumn 30, Issue 6, 2014, Pages 748-752

  Li, Gong Hua ^a   Huang, Jing Fei ^a  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEXOKINASE; HK1 PROTEIN, HUMAN;

ARTICLE; BIOLOGY; CLINICAL TRIAL (TOPIC); ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; METHODOLOGY;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMPUTATIONAL BIOLOGY; GENE EXPRESSION REGULATION, NEOPLASTIC; HEXOKINASE; HUMANS; LUNG NEOPLASMS;

EID: 84897895149     PISSN: 13674803     EISSN: 14602059     Source Type: Journal    
DOI: 10.1093/bioinformatics/btt606     Document Type: Article

References (23)

1. Aggarwal, S. (2010) Targeted cancer therapies. Nat. Rev. Drug Discov., 9, 427-428.
2. Ciardiello, F. and Tortora, G. (2008) Drug therapy: EGFR antagonists in cancer treatment. N. Eng. J. Med., 358, 1160-1174.
3. Gaulton, A. et al. (2012) ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res., 40, D1100-D1107.
4. Hainaut, P. and Plymoth, A. (2013) Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy., Cur. Opin. Oncol., 25, 50-51.
5. Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-674.
6. Huang, D.W. et al. (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc., 4, 44-57.
7. Krupp, M. et al. (2012) RNA-Seq Atlas-a reference database for gene expression profiling in normal tissue by next-generation sequencing. Bioinformatics, 28, 1184-1185.
8. Li, G.H. and Huang, J.F. (2012) CDRUG: a web server for predicting anticancer activity of chemical compounds. Bioinformatics, 28, 3334-3335.
9. Mortazavi, A. et al. (2008) Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods, 5, 621-628.
10. Ngo, V.N. et al. (2006) A loss-of-function RNA interference screen for molecular targets in cancer. Nature, 441, 106-110.
11. Reinhold, W.C. et al. (2012) CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res., 72, 3499-3511.
12. Rempel, A. et al. (1996) Glucose catabolism in cancer cells: amplification of the gene encoding type II hexokinase. Cancer Res., 56, 2468-2471.
13. Sawyers, C. (2004) Targeted cancer therapy. Nature, 432, 294-297.
14. Seo, J.S. et al. (2012) The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res., 22, 2109-2119.
15. Sethi, G. et al. (2012) An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer. PLoS One, 7, e47086B.
16. Shoemaker, R.H. (2006) The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer, 6, 813-823.
17. Siddiqui, A.S. et al. (2006) Sequence biases in large scale gene expression profiling data. Nucleic Acids Res., 34, e83.
18. Siegel, R. et al. (2012) Cancer statistics, 2012. CA Cancer J. Clin., 62, 10-29.
19. Tennant, D.A. et al. (2010) Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer, 10, 267-277.
20. Tiedemann, R.E. et al. (2012) Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome. Cancer Res., 72, 757-768.
21. Tugues, S. et al. (2011) Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol. Aspects Med., 32, 88-111.
22. Wilson, J.E. (2003) Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J. Exp. Biol., 206, 2049-2057.
23. Wolf, A. et al. (2011) Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J. Exp. Med., 208, 313-326.